Ads
related to: hcv polymerase inhibitors for breast cancer- Understand Your Diagnosis
See How A Metastatic Breast
Breast Cancer Treatment Works.
- Resources For Patients
Support For You & Care Partners
View An MBC Treatment Option.
- Get MBC Treatment Info
Connect With A Rep Or Register For
Updates For A Treatment Option.
- MBC Treatment Option
Visit
Patient Site
- Understand Your Diagnosis
Search results
Results From The WOW.Com Content Network
Ledipasvir/sofosbuvir is a substrate for the drug transporters P-Glycoprotein (P-gp) and breast cancer resistance protein (BCRP). [18] Intestinal absorption of these drug transporter substrates may be decreased by inducers such as rifampin and St. John's wort .
Alpelisib is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
It contains sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor; velpatasvir, an HCV NS5A inhibitor; and voxilaprevir an HCV NS3/4A protease inhibitor. [2] [5] The most common adverse reactions include headache, fatigue, diarrhea, and nausea. [6]
Refractory metastatic melanoma, childhood acute lymphoblastic leukaemia, chronic myeloid leukaemia in blast crises, neuroblastoma, non-small cell lung cancer and breast cancer. Myelosuppression, neurotoxicity and paralytic ileus. Vinflunine: IV: As above. Bladder cancer: As per vinblastine. Vinorelbine: IV: As above. Breast cancer and non-small ...
Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir. [2] The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.
Talazoparib, sold under the brand name Talzenna, is an anti-cancer medication used for the treatment of breast cancer and prostate cancer. [6] It is an orally available poly ADP ribose polymerase PARP inhibitor marketed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations. [9]
Ads
related to: hcv polymerase inhibitors for breast cancer